Crinetics Pharmaceuticals Stock Performance
| CRNX Stock | USD 56.06 0.97 1.70% |
Crinetics Pharmaceuticals has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.9, which signifies possible diversification benefits within a given portfolio. Crinetics Pharmaceuticals returns are very sensitive to returns on the market. As the market goes up or down, Crinetics Pharmaceuticals is expected to follow. Crinetics Pharmaceuticals right now shows a risk of 2.42%. Please confirm Crinetics Pharmaceuticals semi variance, and the relationship between the sortino ratio and rate of daily change , to decide if Crinetics Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Crinetics Pharmaceuticals are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Crinetics Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return (1.70) | Five Day Return 3.15 | Year To Date Return 58.41 | Ten Year Return 128.72 | All Time Return 128.72 |
1 | Long Term Investment Analysis - Stock Traders Daily | 09/23/2024 |
2 | Disposition of 14375 shares by Pizzuti Dana of Crinetics Pharmaceuticals at 54.63 subject to Rule 16b-3 | 10/03/2024 |
3 | Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635 | 10/10/2024 |
4 | Crinetics Pharmaceuticals, Inc. Sees Large Growth in Short Interest | 10/15/2024 |
5 | Sage Therapeutics, Inc. Reports Q3 Loss, Tops Revenue Estimates | 10/29/2024 |
6 | Vanguard Group Incs Strategic Acquisition in Crinetics Pharmaceuticals Inc | 11/05/2024 |
7 | Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society Annual Meeti... | 11/12/2024 |
8 | Crinetics Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Strategic Advances and ... | 11/13/2024 |
9 | Crinetics Pharmaceuticals Third Quarter 2024 Earnings US0.96 loss per share | 11/14/2024 |
10 | Crinetics Pharmaceuticals, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts | 11/21/2024 |
| Begin Period Cash Flow | 34 M |
Crinetics |
Crinetics Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 5,447 in Crinetics Pharmaceuticals on August 27, 2024 and sell it today you would earn a total of 159.00 from holding Crinetics Pharmaceuticals or generate 2.92% return on investment over 90 days. Crinetics Pharmaceuticals is currently generating 0.0737% in daily expected returns and assumes 2.4162% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Crinetics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Crinetics Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Crinetics Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Crinetics Pharmaceuticals, and traders can use it to determine the average amount a Crinetics Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0305
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | CRNX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.42 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.07 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Crinetics Pharmaceuticals is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crinetics Pharmaceuticals by adding it to a well-diversified portfolio.
Crinetics Pharmaceuticals Fundamentals Growth
Crinetics Stock prices reflect investors' perceptions of the future prospects and financial health of Crinetics Pharmaceuticals, and Crinetics Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Crinetics Stock performance.
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.24 | ||||
| Operating Margin | (295.25) % | ||||
| Current Valuation | 4.39 B | ||||
| Shares Outstanding | 92.74 M | ||||
| Price To Earning | (12.03) X | ||||
| Price To Book | 6.24 X | ||||
| Price To Sales | 5,004 X | ||||
| Revenue | 4.01 M | ||||
| Gross Profit | (125.49 M) | ||||
| EBITDA | (221.51 M) | ||||
| Net Income | (214.53 M) | ||||
| Cash And Equivalents | 408.51 M | ||||
| Cash Per Share | 7.60 X | ||||
| Total Debt | 51.73 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 15.94 X | ||||
| Book Value Per Share | 10.30 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Earnings Per Share | (3.70) X | ||||
| Market Capitalization | 5.2 B | ||||
| Total Asset | 635.35 M | ||||
| Retained Earnings | (653.7 M) | ||||
| Working Capital | 530.21 M | ||||
| Current Asset | 44.96 M | ||||
| Current Liabilities | 2.41 M | ||||
About Crinetics Pharmaceuticals Performance
Evaluating Crinetics Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Crinetics Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Crinetics Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.1 K | 2.2 K | |
| Return On Tangible Assets | (0.34) | (0.35) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.34) | (0.35) | |
| Return On Equity | (0.40) | (0.38) |
Things to note about Crinetics Pharmaceuticals performance evaluation
Checking the ongoing alerts about Crinetics Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Crinetics Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 4.01 M. Net Loss for the year was (214.53 M) with loss before overhead, payroll, taxes, and interest of (125.49 M). | |
| Crinetics Pharmaceuticals currently holds about 408.51 M in cash with (166.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.6. | |
| Over 95.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Crinetics Pharmaceuticals, Inc. Receives Consensus Recommendation of Moderate Buy from Analysts |
- Analyzing Crinetics Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Crinetics Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Crinetics Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Crinetics Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Crinetics Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Crinetics Pharmaceuticals' stock. These opinions can provide insight into Crinetics Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Crinetics Stock Analysis
When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.